New study pits two back pain injections Head-to-Head

NCT ID NCT07632820

Recruiting now Symptom relief Sponsor: Mayo Clinic Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study compares two common injection treatments for chronic mid-back pain: the erector spinae plane (ESP) block and trigger point injection (TPI). About 76 adults with pain lasting at least three months will be randomly assigned to one treatment. Researchers will track pain levels, physical function, and emotional well-being for up to 12 weeks to see which approach works better.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Bupivacaine
What this could lead to: If this trial succeeds, it could show that one injection method provides better pain relief and function for people with chronic mid-back pain.
What could go wrong: This is a small, early-phase study with only 76 participants. Results may not apply to everyone, and both treatments may offer only temporary relief.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BACK PAIN are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Back Pain myofascial pain syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BACK PAIN

Contacts and locations

Locations

MD Anderson Cancer Center
NOT_YET_RECRUITING

Houston, Texas, 77030, United States
Mayo Clinic
NOT_YET_RECRUITING

Jacksonville, Florida, 32224, United States
Mayo Clinic
RECRUITING

Rochester, Minnesota, 55905, United States
The Ohio State University Wexner Medical Center
NOT_YET_RECRUITING

Columbus, Ohio, 43210, United States
University of Maryland
NOT_YET_RECRUITING

Baltimore, Maryland, 21201, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.